Seres Therapeutics, Inc. (MCRB) company profile
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
About Seres Therapeutics
Pharmaceutical Preparations, SIC 2834
Seres Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops live biotherapeutic product candidates designed to treat and prevent infections and inflammatory and immune diseases. The company engineers oral consortia of cultivated bacteria to restore gastrointestinal barrier integrity, induce immune homeostasis, and prevent pathogen colonization. Its pipeline includes investigational candidates such as SER-155, which addresses bloodstream infections and immune-related enterocolitis, as well as SER-603 and SER-147 for inflammatory bowel diseases and metabolic conditions. Target populations comprise medically vulnerable patients, including individuals undergoing stem cell transplantation, cancer patients on immune checkpoint inhibitors, and people with chronic liver disease.
The company conducts research and development activities and operates dedicated good manufacturing practices capabilities for its live biotherapeutic candidates. It is actively evaluating opportunities across diverse clinical indications, including intensive care, oncology, and transplant settings. Seres Therapeutics maintains its principal executive offices in Cambridge, Massachusetts.
Summary of the business section of Seres Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Seres Therapeutics, Inc.
- Headquarters
- Cambridge, MA
- Address
- 200 Sidney Street 02139
- Phone
- (617) 945-9626
- Website
- serestherapeutics.com
- Employees
- 66, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- MCRB
- Exchange
- Nasdaq
- IPO date
- Jun 26, 2015
- Shares outstanding
- 10M, Aug 3, 2026
- Public float
- $71.94M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Apr 22, 2025
- SEC CIK
- 1609809
- CUSIP
- 81750R201
- ISIN
- US81750R2013
- FIGI
- BBG0099X6859
- Share class FIGI
- BBG0099X6868
- LEI
- 549300GMXBE5NUWISF13
- EIN
- 27-4326290
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Richard N. Kender | See Remarks, Director | 63,492 |
| Thomas DesRosier | See Remarks | 8,258 |
| Kelly Brady | See Remarks | 8,775 |
| Matthew R. Henn | See Remarks | 8,132 |
| Marella Thorell | See Remarks | – |
| Teresa L. Young | See Remarks | 8,557 |
| Moltke Lisa von | See Remarks | 39,875 |
| Eric D. Shaff | Director | 12,936 |
| Stephen Berenson | Director | 3,589 |
| Robert L. Rosiello | Director | – |
| Dennis A. Ausiello | Director | – |
| Willard H. Dere | Director | 31,746 |
| Claire Fraser | Director | – |
| Kurt Graves | Director | – |
| Paul Biondi | Director | 47,619 |
| Hans-Juergen Woerle | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Eric DShaff | $1.78M | $1.45M | $1.02M | $13 | – |
| FY2025 Marella Thorell | $1.11M | $962.20K | $1.02M | $13 | – |
| FY2025 Thomas JDes Rosier | $1.14M | $1.03M | $1.02M | $13 | – |
| FY2024 Eric DShaff | $2.68M | $1.91M | $1.26M | $15 | – |
| FY2024 Marella Thorell | $0 | $0 | $1.26M | $15 | – |
| FY2024 Thomas JDes Rosier | $0 | $0 | $1.26M | $15 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Eric D. Shaff Former President and Chief Executive Officer | $408.33K | – | – | $1.34M | $28.35K | $1.78M | -34% |
| Thomas J. DesRosier Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer | $512.90K | $166.67K | – | $446.29K | $10.17K | $1.14M | -9% |
| Marella Thorell Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer | $494.40K | $166.67K | – | $446.29K | $6.04K | $1.11M | – |
| Matthew Henn President and Chief Scientific Officer | $489.30K | – | $75.68K | $446.29K | $3.08K | $1.01M | – |
| Teresa L. Young Former Executive Vice President and Chief Commercial and Strategy Officer | $489.30K | – | $75.68K | $446.29K | $10.19K | $1.02M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 26, 2015
- Offer price
- $18.00
- Securities offered
- 7,430,555
- Gross proceeds
- $133.75M
- Exchange
- Nasdaq
- First trading day
- Jun 26, 2015
- First-day close
- $51.40+185.6%
- Lock-up ends (est.)
- Dec 23, 2015
“The initial public offering price per share is $18.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 66 full-time permanent employees, which included 14 employees in operations and administration and 52 employees in research and development (which includes clinical and manufacturing).”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 13, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 1, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 26, 2024 | Merger vote | Definitive merger proxy statement |
| Apr 23, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 26, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 22, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 14, 2015 | Name change | Name changed from Seres Health, Inc. to Seres Therapeutics, Inc. |
See a number that looks wrong?